Get the Stockscreener App
111.35
7.12%
-8.8799
Glaukos Corp stock is traded at $111.35, with a volume of 1.69M.
It is down -7.12% in the last 24 hours and down -8.08% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$120.23
Open:
$119.71
24h Volume:
1.69M
Relative Volume:
2.17
Market Cap:
$6.55B
Revenue:
$551.35M
Net Income/Loss:
$-189.33M
P/E Ratio:
-33.83
EPS:
-3.2916
Net Cash Flow:
$-35.09M
1W Performance:
-20.18%
1M Performance:
-8.08%
6M Performance:
+5.95%
1Y Performance:
+16.29%
1-Day Range:
$106.24
$120.55
1-Week Range:
$106.24
$146.71
52-Week Range:
$73.16
$148.11
Glaukos Corp Stock (GKOS) Company Profile
Name
Glaukos Corp
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
111.56 | 7.06B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
86.84 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.81 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.90 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.97 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.75 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Buy |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corp Stock (GKOS) Latest News
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Midday Stock Roundup: Glaukos Corp. Shares Drop 11% - Orange County Business Journal
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest - AD HOC NEWS
Glaukos director Kliman sells $703,800 in stock - Investing.com
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at $146.90 - Investing.com UK
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp stock (US3773221029): eye-care specialist gains attention after FDA approval and strong - AD HOC NEWS
Glaukos (GKOS) price target increased by 12.59% to 154.96 - MSN
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding - Stock Titan
Glaukos (GKOS) Stock Price, News & Analysis - MarketBeat
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares - Stock Titan
Glaukos stock (US3773221029): Director sale signals confidence near 52-week highs - AD HOC NEWS
Glaukos director Gilbert H Kliman sells $675,000 of company stock - Investing.com UK
Glaukos director Gilbert H Kliman sells $675,000 of company stock By Investing.com - Investing.com South Africa
TradingKey - TradingKey
Glaukos Corp stock (US3773221029): Insider files Form 144 for 5,000-share sale - AD HOC NEWS
Glaukos Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
How to watch Glaukos at four upcoming investor conferences - Stock Titan
[144] GLAUKOS Corp SEC Filing - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Number of shareholders of Glaukos Corp – LS:A14VCK - TradingView
Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile - AD HOC NEWS
Glaukos Corp. Hits New 52-Week High at $145.50, Reflecting Strong Growth - Markets Mojo
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares - Investing.com Australia
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares By Investing.com - Investing.com South Africa
Glaukos president & COO Gilliam sells $2.8m in company stock - Investing.com Australia
Glaukos president & COO Gilliam sells $2.8m in company stock By Investing.com - Investing.com South Africa
Glaukos (GKOS) CFO exercises options and sells 10,000 shares under plan - Stock Titan
GLAUKOS (GKOS) President & COO sells 19,573 shares in open-market trade - Stock Titan
GLAUKOS (GKOS) director Leana Wen sells 1,700 shares, holds 19,739 - Stock Titan
Glaukos Corp Leads Innovation in Chronic Eye Disease Treatment with iDose TR and Epioxa Therapies – 2026 Investor Update - Minichart
Glaukos to present May 2026 investor slide deck highlighting iDose TR, Epioxa launch and 2026 guidance - TradingView
[8-K] GLAUKOS Corp Reports Material Event - Stock Titan
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations - Yahoo Finance
UBS Group AG Increases Position in Glaukos Corporation $GKOS - MarketBeat
MSN - MSN
Glaukos Corp Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):